METHOTREXATE SOLUTION

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

METHOTREXATE

Доступна с:

PFIZER CANADA ULC

код АТС:

L01BA01

ИНН (Международная Имя):

METHOTREXATE

дозировка:

25MG

Фармацевтическая форма:

SOLUTION

состав:

METHOTREXATE 25MG

Администрация маршрут:

INTRA-ARTERIAL

Штук в упаковке:

2ML

Тип рецепта:

Prescription

Терапевтические области:

ANTINEOPLASTIC AGENTS

Обзор продуктов:

Active ingredient group (AIG) number: 0107545002; AHFS:

Статус Авторизация:

CANCELLED POST MARKET

Дата Авторизация:

2011-05-03

Характеристики продукта

METHOTREXATE PRODUCT MONOGRAPH
PAGE 1 OF 47
PRODUCT MONOGRAPH
Pr
METHOTREXATE
Methotrexate Tablets USP
Methotrexate Injection USP
Antimetabolite
®T.M. Wyeth
Pfizer Canada Inc., Licensee
17,300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
DATE OF PREPARATION:
April 1, 2003
DATE OF REVISION:
April 21, 2011
SUBMISSION CONTROL NO: 144377, 144378
©
Pfizer Canada Inc.
METHOTREXATE PRODUCT MONOGRAPH
PAGE 2 OF 47
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..............................................................3
SUMMARY PRODUCT INFORMATION
............................................................................3
INDICATIONS AND CLINICAL
USE..................................................................................3
CONTRAINDICATIONS
.......................................................................................................4
WARNINGS AND
PRECAUTIONS......................................................................................6
ADVERSE
REACTIONS......................................................................................................16
DRUG INTERACTIONS
......................................................................................................19
DOSAGE AND
ADMINISTRATION..................................................................................22
OVERDOSAGE
....................................................................................................................29
ACTION AND CLINICAL PHARMACOLOGY
................................................................30
STORAGE AND
STABILITY..............................................................................................32
SPECIAL HANDLING INSTRUCTIONS
...........................................................................32
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................34
PART II: SCIENTIFIC
INFORMATION....................................................................................35
PHARMACEUTICAL
INFORMATION..............